Evolus, Inc. (NASDAQ:EOLS) Insider Rui Avelar Sells 2,252 Shares

Evolus, Inc. (NASDAQ:EOLS) insider Rui Avelar sold 2,252 shares of Evolus stock in a transaction that occurred on Monday, December 23rd. The shares were sold at an average price of $10.85, for a total transaction of $24,434.20. Following the completion of the transaction, the insider now directly owns 366,595 shares in the company, valued at approximately $3,977,555.75. This represents a 0.61 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Evolus Stock Up 4.6 %

Shares of EOLS opened at $11.35 on Friday. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. The company has a 50-day simple moving average of $13.56 and a 200-day simple moving average of $13.75. Evolus, Inc. has a 52 week low of $9.80 and a 52 week high of $17.82. The firm has a market capitalization of $718.69 million, a P/E ratio of -12.47 and a beta of 1.27.

Wall Street Analyst Weigh In

A number of research firms have weighed in on EOLS. Needham & Company LLC reissued a “buy” rating and set a $22.00 target price on shares of Evolus in a research report on Friday, September 13th. HC Wainwright reissued a “buy” rating and set a $27.00 price objective on shares of Evolus in a research report on Thursday, November 7th. Cantor Fitzgerald restated an “overweight” rating on shares of Evolus in a research note on Monday, September 16th. Finally, Barclays lifted their price target on Evolus from $16.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday, September 13th.

Hedge Funds Weigh In On Evolus

Several large investors have recently added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. increased its position in shares of Evolus by 173.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 418,576 shares of the company’s stock valued at $6,781,000 after purchasing an additional 265,635 shares during the period. Bank of New York Mellon Corp boosted its stake in Evolus by 24.6% during the second quarter. Bank of New York Mellon Corp now owns 181,093 shares of the company’s stock worth $1,965,000 after buying an additional 35,760 shares in the last quarter. Armistice Capital LLC acquired a new stake in Evolus during the second quarter worth $3,906,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Evolus in the 3rd quarter valued at $940,000. Finally, Lord Abbett & CO. LLC raised its stake in shares of Evolus by 23.4% in the 3rd quarter. Lord Abbett & CO. LLC now owns 995,449 shares of the company’s stock valued at $16,126,000 after buying an additional 188,685 shares in the last quarter. Institutional investors and hedge funds own 90.69% of the company’s stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.